JATT II Acquisition, a blank check company targeting biotechs and life sciences businesses, filed on Friday with the SEC to raise up to $60 million in an initial public offering. JATT II Acquisition is led by CEO and Chairman Someit Sidhu, who has founded and led several healthcare companies, most recently Khanda Therapeutics, where he serves as CEO. The SPAC plans to target healthcare and healthcare-related businesses, with a primary emphasis on biotechnology and broader life sciences.
Read the full article: SPAC JATT II Acquisition Files for a $60M IPO, Targeting Biotech and Life Sciences //
Source: https://www.renaissancecapital.com/IPO-Center/News/117659/SPAC-JATT-II-Acquisition-files-for-a-$60-million-IPO-targeting-biotech-and-
